The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final overall survival analysis for a phase 3 randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834).
 
Kyoji Tsurumi
No Relationships to Disclose
 
Satoru Miura
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; Janssen Oncology; Novocure
Speakers' Bureau - Amgen; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Merck KGaA; MSD; Novartis; Novocure; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda
 
Toshihiro Misumi
Honoraria - Miyarisan pharmaceutical
Consulting or Advisory Role - Anaut Inc.
 
Hiroshige Yoshioka
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Delta-Fly Pharma; Lilly; Merck; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Delta-Fly Pharma
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Delta-Fly Pharma (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst)
 
Takaaki Tokito
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Chugai Pharma; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical
 
Yuki Sato
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Daiichi Sankyo/Arqule; Janssen; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Travel, Accommodations, Expenses - Regeneron
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly Japan; Merck; Nippon Boehringer Ingelheim; Nippon Kayaku; Novar Pharma; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Lilly Japan; Pfizer
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer Pharma Japan. (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Delta-Fly Pharma (Inst); EPS Corporation (Inst); Fortrea Japan (Inst); Gilead Sciences (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel International Inc (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Naoki Furuya
No Relationships to Disclose
 
Takayasu Kurata
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Amgen; AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Janssen; MSD Oncology (Inst); Takeda (Inst)
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; Boehringer Ingelheim; Chugai Pharma; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; DaiichiSankyo; Johnson & Johnson/Janssen; Merck KGaA; MSD; Novocure
Research Funding - Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer; BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst)
 
Hidehito Horinouchi
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; BlossomHill Therapeutics, Inc.; Chugai Pharma; Daiichi Sankyo; Genmab; Novocure; Seagen; Yuhan
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BlossomHill Therapeutics, Inc. (Inst); BMKK (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yuichi Takiguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin International; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; MSD Oncology; Taiho Pharmaceutical
 
Yasuhiro Goto
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Chugai Pharma; Kyowa Kirin International; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Kentaro Tanaka
Honoraria - Astrazeneca; Bristol-Myers Squibb/Ono Pharmaceutical; Chugai/Roche; Daiichi Sankyo/UCB Japan; kyowa kirin; Lilly Japan; Merck; MSD; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Pfizer
 
Masahide Mori
Speakers' Bureau - Abbvie; Astrazeneca; Boehringer Ingelheim; Chugai Pharma; Daiici-Sankyo; Kyowa-kirin; Lilly; MSD; Nihonkayaku; Novartis; Ono pharmacoceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst)
 
Satoshi Ikeda
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca
Research Funding - AstraZeneca; Chugai Pharma (Inst)
 
Eiki Ichihara
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Janssen; Kyowa Kirin International; Merck; Novartis; Pfizer; Takeda
Research Funding - Janssen
 
Hiroshi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Hisamitsu Pharmaceutical; Lilly; Merck KGaA; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Janssen; MSD Oncology
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroaki Okamoto
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)